Genetic variability of phase II metabolism by a glutathione S-transferase enzyme coded for by GSTM1 has been associated with dyskinesia experienced in risperidone-treated patients (de Leon et al., 2005b). Here, GSTM1 is linked to drug-induced dyskinesia.